Zenas BioPharma, Inc.
ZBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Zenas BioPharma, Inc. (ZBIO) is listed under Biotechnology. The company carries a $1.17B market cap, placing it firmly in the small-cap category. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Market Cap
$1.17B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-8.19
EPS (TTM)
$-9.10
EPS (Fwd)
$-2.27
ROE
-137.1%
ROA
-29.1%
Cash
$717.2M
Total Debt
$266.8M
Free CF
-$166.3M
52W Change
95.0%
Annual Financials
Cash vs Debt
With $717.2M in cash and $266.8M in debt, ZBIO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$166.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -137.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZBIO.